

# OBSTRUCTIVE SLEEP APNEA IN AMYOTROPHIC LATERAL SCLEROSIS: DIAGNOSTIC CHALLENGES AND PREDICTIVE MODELING

Valentina Malanchini (1); Dario Bottignole (1)(2)(3); Andi Nuredini (1); Giulia Balella (1)(2)(3);  
Francesco Rausa (2)(3); Liborio Parrino (1)(2)(3); Lucia Zinno (1); Carlotta Mutti (2)(3).

1) Neurology Unit, Department of General and Specialized Medicine, Parma University Hospital, A. Gramsci Street 14, 43126 Parma, Italy.

2) Sleep Disorders Center, Department of Medicine and Surgery, Parma University Hospital, A. Gramsci Street 14, 43126 Parma, Italy.

3) "Mario Giovanni Terzano" Interdepartmental Centre for Sleep Medicine, University of Parma, A. Gramsci Street 14, 43126 Parma, Italy.

## INTRODUCTION

- Amyotrophic lateral sclerosis (ALS) includes both motor and **non-motor symptoms**, such as sleep disturbances.
- Although their **high prevalence** and **clinical significance**, sleep-related issues are still **overlooked** during ALS patients' clinical assessments
- Current knowledge revolves around **subjective measures**.

## AIMS

Explore sleep disorders' **prevalence**, **characteristics**, and **clinical impact** among ALS patients

## METHODS

Observational, monocentric (University Hospital of Parma, Italy), prospective study  
Variables collected:

**Anthropometric data** (e.g., age, weight, height)

**Disease descriptors** (e.g., symptom onset, system primarily affected, initial need for supportive treatments, etc.)

**Disease severity** (ALS-FRS-r)

**Cognitive performances** (ECAS tool)

**Sleep quality** (PSQI)

**Sleep perception** (DBAS-16)

**Daytime sleepiness** (ESS)

**Risk of OSA** (BQ)

**Health-related quality of life** (SF-36)

**Level 3 polysomnography** (home sleep apnea testing) with additional specific electrodes for muscle activity




Fig. 1: ROC curve representing the reliability in predicting the presence of OSA with a 4-variable model: BMI, PSQI score, biological sex and pseudobulbar symptoms.

## RESULTS

**22 ALS patients enrolled:** 70.57 ± 10.8 years; 12 males and 10 females; mean disease duration 21.3 ± 21.64 months.

**Sleep questionnaires:** 86.4% reported sleep disturbances (20% insomnia symptoms, 55% nocturnal leg cramps, 15% RLS symptoms)

- *Comorbid insomnia* ↔ FTD-related **behavioral changes** (p = 0.0006)
- *Female patients* → Worse subjective **sleep quality** (p = 0.04) and higher **daytime fatigue** (p = 0.04).

**Polysomnography data:** 57.1% of OSA, 23.8% of PLMD → Mild (5-15/h) 33.3%, Moderate (15-30/h) 14.3%, Severe (>30/h) 9.5%

- *Male patients* → Higher odds of OSA (72.7% vs 40%), **higher AHI values** (p = 0.01), **higher ESS scores** (p = 0.05)
- *Berlin Questionnaire* → Only 3 out of 21 patients had a high risk of OSA (vs 12 diagnosed with HSAT, and 5 with moderate-severe forms)

**OSA risk predictive score:** Body Mass Index, Pittsburgh Sleep Quality Index total score, sex, and bulbar involvement (Fig. 1)

- 87.5% specificity, 80% accuracy, AUC 0.911

No correlation between sleep disorders and ALS severity (ALS-FRS-r score and subscores)

**Survival analysis:** Detrimental correlation between AHI values (cut-off threshold: 3.8 events/h) and 12-month survival (67% vs. 100%) (Fig. 2)

## DISCUSSION

- **High prevalence** of sleep disorders among ALS patients, confirmed with both subjective and objective measures;
- ALS severity scales could be limited for a multidimensional approach to these patients, neglecting specific domains (e.g., bulbar and respiratory systems);
- Traditional screening tools might be inadequate for ALS patients due to poor sensitivity;
- **Predictive model for OSA risk** integrating BMI, sex, PSQI, and bulbar involvement displayed 80% accuracy;
- **ALS patients' peculiar features** (increased sensitivity to muscle atonia, respiratory muscle exhaustion, loss of bulbar motor neurons) could foster upper airways collapsibility and impair loop gain control;
- **Intermittent hypoxia** due to obstructive apnea may promote neuronal death, oxidative stress, and inflammation, supporting a worse prognosis in ALS+OSA patients;
- **Treatment with NIV** can neutralize the negative survival impact of OSA and also improve quality of life.
- **Limitations:** small sample size, due to ALS epidemiology and monocentric design.




Fig.2: Kaplan-Meier survival curve estimating patients' survival probability over time stratified in two groups according to the AHI value, considering a cut-off of 3.8 events/h.

## CONCLUSIONS

- Include **sleep evaluation** in the **routine workup** of ALS patients;
- **Include complementary information** in conventional screening processes;
- Consider also other respiratory patterns suggestive of **excessive respiratory effort**;
- **Prompt treatment** of sleep-breathing disorders mitigates the negative impact on prognosis.

